Objective
SAPHIR aims to develop vaccine strategies effective against endemic pathogens responsible for high economic losses in livestock in order to strengthen the profitability of food animal systems, improve animal welfare and reduce xenobiotic usage in farming with a One Health perspective.
SAPHIR will bring novel vaccine strategies to the market i) at short term, with several promising vaccines brought to demonstration (RTL6), ii) at long term, with cutting edge strategies brought at proof of concept (RTL3) and iii) in line with socio-economic requirements. SAPHIR has selected two representative pathogens of pigs (Porcine Reproductive and Respiratory Syndrome Virus and Mycoplasma hyopneumoniae), chickens (Eimeria and Clostridium perfringens) and cattle (Bovine Respiratory Syncytial Virus, Mycoplasma bovis) to develop generic vaccine approaches applicable to other pathogens.
SAPHIR will issue i) knowledge of immune mechanisms of protection, ii) affordable, safe and multivalent vaccines with DIVA properties, iii) efficient adjuvants targeting dendritic cells, optimal formulations, new mucosal and skin delivery systems, a new generation of DNA vectors and viral replicon platforms for fostering an earlier and longer duration of immunity including the perinatal period, and iv) basal biomarkers of individual immuno-competence for future breeding strategies. The SAPHIR dissemination and training programme includes creation of an integrated health management website, launch of a Global Alliance for Veterinary Vaccines and organization of workshops directed at food animal system stakeholders. This will ensure optimal research translation of SAPHIR outputs to market and field applications.
SAPHIR brings together interdisciplinary expertise from fourteen academic institutes including a Chinese partner, five SMEs and two pharmaceutical companies.
Fields of science
Programme(s)
Funding Scheme
RIA - Research and Innovation action
Coordinator
75007 Paris Cedex 07
France
See on map
Participants (21)
CF24 0DE Cardiff
See on map
3003 Bern
See on map
2905 AT Capelle Aan Den Ijssel
See on map
28037 Madrid
See on map
75015 Paris
See on map
26900 Lodi
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
200241 Shanghai
See on map
NW1 0NH London
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
6708 PB Wageningen
See on map
750 07 Uppsala
See on map
02 787 Warszawa
See on map
GU24 0NF Woking
See on map
NW1 OTU London
See on map
3012 Bern
See on map
1015 Lausanne
See on map
9000 Gent
See on map
EH8 9YL Edinburgh
See on map
0349 Oslo
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
06511 Carros
See on map
5 Killester
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
L69 7ZX Liverpool
See on map